Brought to you by 
Med BioGene closes first tranche of financing
10 Dec 2008
Executive Summary
Med BioGene (diagnostic and prognostic tests for cancer and cardiovascular disease) has closed the first tranche of a public offering. It sold 10.7mm units at $Cdn0.15 each, grossing $Cdn1.6mm ($1.5mm). Each unit consists of one common share and one-half of a share purchase warrant. Each whole warrant is exercisable into one common share at $Cdn0.20 for two years. PI Financial was the placement agent.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Med BioGene closes first tranche of financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice